Table 2 Progression-free survival within each treatment arm by baseline biomarker levels dichotomized at the median
Plasma Biomarker | Cabozantinib | Everolimus | Pinteraction | ||||
|---|---|---|---|---|---|---|---|
Median PFS, mo | HR (95% CI) | Median PFS, mo | HR (95% CI) | ||||
≥median biomarker | <median biomarker | ≥median biomarker | <median biomarker | ||||
CA9 | 7.4 | 7.4 | 0.87 (0.65, 1.17) | 3.9 | 3.8 | 0.89 (0.67, 1.17) | 1.0 |
HGF | 5.6 | 9.2 | 1.77 (1.30, 2.40)* | 3.7 | 5.4 | 1.48 (1.12, 1.95)* | 0.47 |
MET | 7.4 | 7.4 | 1.00 (0.74, 1.35) | 3.7 | 4.1 | 1.16 (0.88, 1.53) | 0.45 |
GAS6 | 7.2 | 9.1 | 1.31 (0.97, 1.77) | 3.7 | 3.9 | 1.07 (0.81, 1.40) | 0.36 |
AXL | 6.0 | 9.1 | 1.45 (1.07, 1.96)* | 3.8 | 3.9 | 0.92 (0.70, 1.21) | 0.02* |
VEGF | 5.6 | 9.2 | 1.57 (1.17, 2.12)* | 3.7 | 4.1 | 1.15 (0.87, 1.51) | 0.16 |
VEGFR2 | 7.4 | 7.4 | 0.89 (0.66, 1.19) | 4.4 | 3.7 | 0.88 (0.67, 1.16) | 0.94 |
IL-8 | 7.3 | 7.4 | 1.10 (0.82, 1.49) | 3.7 | 5.3 | 1.40 (1.06, 1.85)* | 0.21 |